Published on 14 January 2009, 02:08
The new study shows that medicines such as orphenadrine (Disipal) and biperiden (Akineton) do not stand out as abused drugs from a pharmacoepidemiological perspective. Previously, some smaller studies have been published that indicate that these drugs have abuse potential.
Anticholinergic anti-Parkinson medicines are very fat-soluble and many may experience a “kick” when they take these medicines. However, from an epidemiological perspective, we have not been able to confirm abuse in the Norwegian population.
Pharmacoepidemiological methods are relatively coarse and the study cannot exclude that abuse takes place. However the findings indicate that it is not a widespread phenomenon.
The drugs were originally introduced to treat Parkinson’s disease, but are not often used for this today. The study shows that orphenadrine and biperiden are used to treat Parkinson-like adverse effects after use of anti-psychotic medicines.
The study builds on figures from the Norwegian Prescription Database in 2004. Orfenadrin was withdrawn from the Norwegian market in 2005.
Reference: Gjerden P, Bramness JG, Slørdal L. The use and potential abuse of antichiolinergic antiparkinson drugs in Norway: a pharmacoepidemiologcal study. Br. J. Clin. Pharmacology, 2008 Dec 16 (e-pub ahead of print)
Contact: Nasjonalt folkehelseinstitutt, Tel: 21 07 70 00, Telefax: 22 35 36 05
Source: Folkehelseinstitutt
480 Views
E-Mail Newsletter RSS Feed
Related News